biote Corp.

biote Corp. (Nasdaq: BTMD) is a healthcare company focused on hormone optimization that reached the public markets through a merger with Haymaker Acquisition Corp. III, a blank-check vehicle sponsored by Haymaker Sponsor III, LLC that completed its SPAC IPO in 2021. The business combination closed in 2022, establishing biote as a publicly traded provider of bioidentical hormone replacement therapy services through a practitioner-certification model. A Form 8-K was filed with the SEC on May 18, 2026, continuing the company's routine reporting obligations as a de-SPAC issuer. Visit SpacDesk to sign up and access full filing history, sponsor data, and analytics on BTMD and the broader de-SPAC universe.